Terumo Q4 2025 Earnings Report

Terumo EPS Results

• Actual EPS: $0.08
• Consensus EPS: $0.15
• Beat/Miss: Missed by -$0.07
• One Year Ago EPS: N/A

Terumo Revenue Results

• Actual Revenue: $1.79 billion
• Expected Revenue: $1.79 billion
• Beat/Miss: Missed by -$7.40 million
• YoY Revenue Growth: N/A

Terumo Announcement Details

• Quarter: Q4 2025
• Date: 5/14/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Terumo (OTCMKTS:TRUMY) Corporation is a Japan-based medical technology company that develops, manufactures and sells products used in hospitals, clinics and other health care settings. Founded in 1921, the company has grown from producing clinical thermometers into a global provider of medical devices and related solutions.

Terumo’s businesses include cardiovascular and vascular intervention products, such as catheters, guidewires and other devices used in the treatment of heart and vascular conditions. The company also supplies blood management products, including blood bags and automated systems, as well as hospital products such as syringes, infusion systems and injection-related devices. In addition, Terumo develops technologies for therapeutic areas including neurovascular care, aortic treatment and cell and gene therapies.

Terumo serves health care providers and patients in Japan and international markets across the Americas, Europe, Asia and other regions. Its products are marketed through a combination of direct operations, subsidiaries and distribution networks, supporting medical professionals in areas including cardiovascular care, blood management and general hospital practice.